|
43 Companies |
|
55 Products |
|
55 Products |
|
60 Mechanisms of Action |
|
1 Trial |
|
670 News |
|
| «12345678910111213...1314» |
- Mozobil (plerixafor) / Sanofi
New P1 trial: Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disease Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disease (clinicaltrials.gov) - Dec 12, 2016
P1, N=6, Not yet recruiting, Sponsor: Alessandra Biffi
- ||||| Enrollment closed, Enrollment change: Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion (clinicaltrials.gov) - Dec 2, 2016
P3, N=86, Active, not recruiting, Sponsor: Cerus Corporation
Recruiting --> Active, not recruiting | N=70 --> 86
- Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
Trial initiation date, Trial primary completion date: Study of SANGUINATE™ In the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive Crisis (clinicaltrials.gov) - Nov 30, 2016
P2, N=24, Recruiting, Sponsor: Prolong Pharmaceuticals
Recruiting --> Active, not recruiting | N=70 --> 86 Initiation date: Jun 2015 --> Nov 2016 | Trial primary completion date: Dec 2016 --> Sep 2017
- New trial: Vitamin D and Bisphosphonates in the Treatment of Sickle Cell Disease (clinicaltrials.gov) - Nov 23, 2016
P=N/A, N=80, Active, not recruiting, Sponsor: Società Italiana Talassemie ed Emoglobinopatie
- Enrollment change: Fertility Preservation in Women Who Will Have Gonadotoxic Therapy or Hematopoetic Stem Cell Transplantation, and in Women With Sickle Cell Disease (clinicaltrials.gov) - Nov 16, 2016
P=N/A, N=22, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Initiation date: Jun 2015 --> Nov 2016 | Trial primary completion date: Dec 2016 --> Sep 2017 N=10 --> 22
- Trial completion, Enrollment change, Trial primary completion date: Role of Placenta Growth Factor in Sickle Acute Chest Syndrome (clinicaltrials.gov) - Nov 15, 2016
P=N/A, N=136, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
N=10 --> 22 Active, not recruiting --> Completed | N=175 --> 136 | Trial primary completion date: Dec 2016 --> Dec 2012
- azithromycin / Generic mfg.
New P1/2 trial: Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease (clinicaltrials.gov) - Nov 9, 2016
P1/2, N=40, Recruiting, Sponsor: Vanderbilt University
- budesonide inhalation suspension / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date: Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial (clinicaltrials.gov) - Nov 8, 2016
P1, N=30, Active, not recruiting, Sponsor: Vanderbilt University
Active, not recruiting --> Completed | N=175 --> 136 | Trial primary completion date: Dec 2016 --> Dec 2012 Recruiting --> Active, not recruiting | N=20 --> 30 | Trial primary completion date: Sep 2016 --> Dec 2016
- Enrollment open: A Comprehensive Care Plan for Pediatric Patients With Vaso-Occlusive Crises (clinicaltrials.gov) - Nov 3, 2016
P=N/A, N=20, Recruiting, Sponsor: Valley Anesthesiology Consultants
Recruiting --> Active, not recruiting | N=20 --> 30 | Trial primary completion date: Sep 2016 --> Dec 2016 Not yet recruiting --> Recruiting
- Enrollment closed, Trial initiation date, Trial primary completion date: PArTNER: PATient Navigator to rEduce Readmissions (clinicaltrials.gov) - Nov 1, 2016
P=N/A, N=1300, Active, not recruiting, Sponsor: University of Illinois at Chicago
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Initiation date: Oct 2014 --> Jul 2014 | Trial primary completion date: Apr 2016 --> Dec 2016
- | PF-04447943 / Pfizer
Trial completion, PK/PD data, Enrollment change: Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease (clinicaltrials.gov) - Nov 1, 2016
P1b, N=30, Completed, Sponsor: Pfizer
Recruiting --> Active, not recruiting | Initiation date: Oct 2014 --> Jul 2014 | Trial primary completion date: Apr 2016 --> Dec 2016 Recruiting --> Completed | N=64 --> 30
- EPEG (pegylated recombinant erythropoietin) / Cadila, Prolong Pharma
New P1 trial: A Study of EPEG in Beta Thalassemia Patients (clinicaltrials.gov) - Nov 1, 2016
P1, N=6, Not yet recruiting, Sponsor: Prolong Pharmaceuticals
- ||||||| vepoloxamer (MST-188) / Savara
Trial completion: Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC) (clinicaltrials.gov) - Oct 28, 2016
P3, N=388, Completed, Sponsor: Mast Therapeutics, Inc.
Recruiting --> Completed | N=64 --> 30 Recruiting --> Completed
- || vepoloxamer (MST-188) / Savara
Trial completion, Enrollment change, Trial primary completion date: EPIC-E: Evaluation of Repeat Administration of Purified Poloxamer 188 (clinicaltrials.gov) - Oct 28, 2016
P3, N=16, Completed, Sponsor: Mast Therapeutics, Inc.
Recruiting --> Completed Recruiting --> Completed | N=388 --> 16 | Trial primary completion date: Jun 2016 --> Sep 2016
- Trial completion, Enrollment change: Improving Parental Psychosocial Functioning and Early Developmental Outcomes in Children With Sickle Cell Disease (clinicaltrials.gov) - Oct 27, 2016
P=N/A, N=64, Completed, Sponsor: The University of The West Indies
Recruiting --> Completed | N=388 --> 16 | Trial primary completion date: Jun 2016 --> Sep 2016 Recruiting --> Completed | N=140 --> 64
- Trial primary completion date: Effects of Spirulina on Cardiac Functions in Children With Beta Thalassemia Major (clinicaltrials.gov) - Oct 25, 2016
P4, N=60, Active, not recruiting, Sponsor: Tanta University
Recruiting --> Completed | N=140 --> 64 Trial primary completion date: Oct 2016 --> Mar 2017
- Enrollment closed: Effect of Spirulina Compared to Amlodipine on Cardiac Iron Overload in Children With Beta Thalassemia (clinicaltrials.gov) - Oct 25, 2016
P=N/A, N=40, Active, not recruiting, Sponsor: Tanta University
Trial primary completion date: Oct 2016 --> Mar 2017 Recruiting --> Active, not recruiting
- Enrollment closed: Effect of Spirulina on Liver Fibrosis by Transient Elastography in Beta Thalassemic Children With Hepatitis C (clinicaltrials.gov) - Oct 25, 2016
P4, N=60, Active, not recruiting, Sponsor: Tanta University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Enrollment closed: Effect of Spirulina on Serum Hyaluronic Acid in Beta Thalassemic Children With Hepatitis C (clinicaltrials.gov) - Oct 25, 2016
P4, N=60, Active, not recruiting, Sponsor: Tanta University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Enrollment closed: Effect of Spirulina on Liver Iron Concentration in Beta Thalassemic Children With Hepatitis C (clinicaltrials.gov) - Oct 25, 2016
P4, N=30, Active, not recruiting, Sponsor: Tanta University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Enrollment closed, Immunomodulating: the Potential Immunomodulatory Effects of Spirulina on Thalassemic Children (clinicaltrials.gov) - Oct 25, 2016
P4, N=60, Active, not recruiting, Sponsor: Tanta University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Enrollment closed: CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant (clinicaltrials.gov) - Oct 5, 2016
P2, N=35, Active, not recruiting, Sponsor: New York Medical College
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Phase classification, Enrollment change, Trial primary completion date: SOMMEDREP: Sleep Respiratory Disorders Evaluation in Sickle Cell Disease Children (clinicaltrials.gov) - Sep 29, 2016
P=N/A, N=120, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Recruiting --> Active, not recruiting Phase classification: P2/3 --> P=N/A | N=280 --> 120 | Trial primary completion date: Mar 2017 --> Aug 2018
- tadalafil / Generic mfg.
Enrollment change, Trial withdrawal, Trial primary completion date: Tadalafil for Treatment of Priapism in Men With Sickle Cell Anemia (clinicaltrials.gov) - Sep 21, 2016
P2, N=0, Withdrawn, Sponsor: Johns Hopkins University
Phase classification: P2/3 --> P=N/A | N=280 --> 120 | Trial primary completion date: Mar 2017 --> Aug 2018 N=20 --> 0 | Terminated --> Withdrawn | Trial primary completion date: Dec 2010 --> Aug 2009
- Trial completion, Enrollment change, Trial primary completion date: High-Tc Susceptometer to Monitor Transfusional Iron Overload (clinicaltrials.gov) - Sep 21, 2016
P2, N=99, Completed, Sponsor: Columbia University
N=20 --> 0 | Terminated --> Withdrawn | Trial primary completion date: Dec 2010 --> Aug 2009 Recruiting --> Completed | N=190 --> 99 | Trial primary completion date: Aug 2016 --> Oct 2015
- New trial: DREAM²t: Sickle Cell Anemia and Cerebral Microcirculation : Multimodal Exploration (clinicaltrials.gov) - Sep 21, 2016
P=N/A, N=64, Completed, Sponsor: Imagine Institute
- Trial completion: A New Reagent Assay Examining Natural Parvovirus B19 Infection in Sickle Cell Disease (clinicaltrials.gov) - Sep 19, 2016
P=N/A, N=24, Completed, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Completed | N=190 --> 99 | Trial primary completion date: Aug 2016 --> Oct 2015 Active, not recruiting --> Completed
- New trial: The Prevalence and Severity of HCV Infection in Thalassemia Major and Thalassemia Intermedia in Siriraj Hospital (clinicaltrials.gov) - Sep 16, 2016
P=N/A, N=246, Recruiting, Sponsor: Mahidol University
- Trial completion, Trial primary completion date: Fertility Preservation in Women Who Will Have Gonadotoxic Therapy or Hematopoetic Stem Cell Transplantation, and in Women With Sickle Cell Disease (clinicaltrials.gov) - Sep 13, 2016
P=N/A, N=10, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Active, not recruiting --> Completed Suspended --> Completed | Trial primary completion date: Aug 2019 --> Sep 2016
- deferasirox tablet for oral suspension / Generic mfg., deferiprone / Generic mfg.
Trial primary completion date: Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia (clinicaltrials.gov) - Sep 8, 2016
P1/2, N=20, Active, not recruiting, Sponsor: Children's Hospital of Philadelphia
Suspended --> Completed | Trial primary completion date: Aug 2019 --> Sep 2016 Trial primary completion date: Aug 2016 --> Jan 2017
- Trial primary completion date: Study of Decitabine and Tetrahydrouridine (THU) in Patients With Sickle Cell Disease (clinicaltrials.gov) - Sep 2, 2016
P1, N=25, Active, not recruiting, Sponsor: The Cleveland Clinic
Trial primary completion date: Aug 2016 --> Jan 2017 Trial primary completion date: Aug 2016 --> Dec 2016
- Trial completion: iTransition: Patient-Provider Tools to Improve the Transition to Adult Care in Sickle Cell Disease (clinicaltrials.gov) - Aug 29, 2016
P=N/A, N=72, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
Trial primary completion date: Aug 2016 --> Dec 2016 Active, not recruiting --> Completed
- Mozobil (plerixafor) / Sanofi
Enrollment open: DrepaMob: Assessment of Tolerance of Mobilizing Peripheral Hematopoietic Stem Cells by Plerixafor in Sickle Cell Patients (clinicaltrials.gov) - Aug 26, 2016
P1/2, N=5, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment closed, Trial primary completion date: Study of Decitabine and Tetrahydrouridine (THU) in Patients With Sickle Cell Disease (clinicaltrials.gov) - Aug 23, 2016
P1, N=25, Active, not recruiting, Sponsor: The Cleveland Clinic
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Aug 2016
- Trial completion: The Link Between Anemia and Deficits in Memory and Attention in Individuals With Sickle Cell Disease (clinicaltrials.gov) - Aug 20, 2016
P=N/A, N=120, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Aug 2016 Recruiting --> Completed
- hydroxyurea / Generic mfg.
New trial, HEOR, Compliance: Study of Hydroxyurea to Treat Sickle Cell Disease (clinicaltrials.gov) - Aug 16, 2016
P=N/A, N=50, Completed, Sponsor: Mersin University
- Enrollment closed, HEOR: Decision Aid for Therapeutic Options In Sickle Cell Disease (clinicaltrials.gov) - Aug 12, 2016
P=N/A, N=120, Active, not recruiting, Sponsor: Emory University
Recruiting --> Completed Recruiting --> Active, not recruiting
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial primary completion date: A Phase II Trial of Regadenoson in Sickle Cell Anemia (clinicaltrials.gov) - Aug 11, 2016
P2, N=100, Recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2016 --> Oct 2016
- Trial completion, Enrollment change, Trial primary completion date: Evaluation of Non-invasive Endothelial Function in Children Sickle by Vascular Ultrasound (clinicaltrials.gov) - Aug 11, 2016
P=N/A, N=31, Completed, Sponsor: University Hospital, Toulouse
Trial primary completion date: Jun 2016 --> Oct 2016 Recruiting --> Completed | N=64 --> 31 | Trial primary completion date: Sep 2016 --> Feb 2013
- ||| ticagrelor / Generic mfg.
Enrollment closed, Trial primary completion date: Hestia2: A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease (clinicaltrials.gov) - Aug 8, 2016
P2b, N=90, Active, not recruiting, Sponsor: AstraZeneca
Recruiting --> Completed | N=64 --> 31 | Trial primary completion date: Sep 2016 --> Feb 2013 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Nov 2016
- Trial completion, Enrollment change: Blood Flow and Pain Crises in People With Sickle Cell Disease (clinicaltrials.gov) - Aug 6, 2016
P=N/A, N=94, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Nov 2016 Recruiting --> Completed | N=120 --> 94
- New trial: Feasibility and Efficacy of a Home-based, Computerized Cognitive Training Program in Pediatric Sickle Cell Disease (clinicaltrials.gov) - Aug 5, 2016
P=N/A, N=134, Recruiting, Sponsor: Steven J. Hardy
- hydroxyurea / Generic mfg.
Trial completion, Enrollment change: State Of The Art Functional Imaging In Sickle Cell Disease (clinicaltrials.gov) - Aug 3, 2016
P=N/A, N=38, Completed, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Completed | N=120 --> 94 Recruiting --> Completed | N=60 --> 38
- Trial completion, Enrollment change, Trial primary completion date: Evaluation of the Hemostatic Potential in Sickle Cell Disease Patients (clinicaltrials.gov) - Jul 28, 2016
P=N/A, N=64, Completed, Sponsor: Brugmann University Hospital
Recruiting --> Completed | N=60 --> 38 Recruiting --> Completed | N=80 --> 64 | Trial primary completion date: Sep 2017 --> Jul 2016
- | Trial completion: Pediatrics:Chlamydia, Sickle Cell Anemia and Stroke Risk - Ancillary to STOP II (clinicaltrials.gov) - Jul 27, 2016
P=N/A, N=0, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting --> Completed | N=80 --> 64 | Trial primary completion date: Sep 2017 --> Jul 2016 No longer recruiting --> Completed
- | Trial completion: Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia (clinicaltrials.gov) - Jul 27, 2016
P2, N=30, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
No longer recruiting --> Completed Recruiting --> Completed
- | Trial completion: Induction of Stable Chimerism for Sickle Cell Anemia (clinicaltrials.gov) - Jul 27, 2016
P2, N=0, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting --> Completed No longer recruiting --> Completed
- Trial completion, Enrollment change: Added Value of Speckle Tracking in the Evaluation of Patients With Sickle Cell Disease (clinicaltrials.gov) - Jul 26, 2016
P=N/A, N=62, Completed, Sponsor: Brugmann University Hospital
No longer recruiting --> Completed Recruiting --> Completed | N=40 --> 62
- Trial completion: Single-center Prospective Evaluation of Sickle Cell Patient Care in the CHU Brugmann Emergency Department (clinicaltrials.gov) - Jul 22, 2016
P=N/A, N=104, Completed, Sponsor: Brugmann University Hospital
Recruiting --> Completed | N=40 --> 62 Active, not recruiting --> Completed
- New trial: Evaluation of Non-invasive Endothelial Function in Children Sickle by Vascular Ultrasound (clinicaltrials.gov) - Jul 12, 2016
P=N/A, N=64, Recruiting, Sponsor: University Hospital, Toulouse